HOWL: Werewolf Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 86.01
Enterprise Value ($M) -11.20
Book Value ($M) 89.38
Book Value / Share 2.01
Price / Book 0.96
NCAV ($M) 75.18
NCAV / Share 1.69
Price / NCAV 1.14

Profitability (mra)
Return on Invested Capital (ROIC) -0.49
Return on Assets (ROA) -0.35
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 10.10
Current Ratio 10.10

Balance Sheet (mrq) ($M)
Current Assets 125.83
Assets 140.04
Liabilities 50.66
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
4 days ago 13G/A Bank Of America Corp /de/ 4.90 2.93
4 days ago 13G/A PFM Health Sciences, LP 7.80
5 days ago 13G/A Rubric Capital Management LP 3.05 -31.08
6 days ago 13G/A Adage Capital Management, L.P. 4.58
05-07 13D/A Ra Capital Management, L.p. 14.20 0.22
12-21 13G Adage Capital Partners Gp, L.l.c. 8.38

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 184,351 607,953 30.32
2024-11-14 172,198 540,500 31.86
2024-11-13 110,601 664,233 16.65
2024-11-12 35,501 399,344 8.89

(click for more detail)

Similar Companies
GOSS – Gossamer Bio, Inc. HALO – Halozyme Therapeutics, Inc.
HLVX – HilleVax, Inc. HUMA – Humacyte, Inc.
IBRX – ImmunityBio, Inc.


Financial data and stock pages provided by
Fintel.io